Real world study of Amphotericin B Colloidal Dispersion (ABCD) in the treatment of invasive fungal disease

A multicenter, retrospective, real-world study of Amphotericin B Colloidal Dispersion (ABCD) in the treatment of invasive fungal disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055851

Enrollment

Unknown

Registered

2022-01-20

Start date

2022-02-01

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive fungal disease

Interventions

Patients treated with ABCD for invasive fungal disease:none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. No age limit, no gender limit; 2. Patients with indications for antifungal therapy, as determined by the investigator; 3. Patients treated with ABCD after failure of previous antifungal therapy.

Exclusion criteria

Exclusion criteria: 1. Patients with incomplete data or other factors affecting the judgment of clinical efficacy; 2. Patients whose clinical efficacy of previous antifungal therapy cannot be evaluated.

Design outcomes

Primary

Measure	Time frame
Therapeutic response rate;	—

Secondary

Measure	Time frame
Six-week survival rate;Incidence of adverse reactions;	—

Countries

China

Contacts

Public ContactJiang Erlie

Hematology Hospital of Chiese Academy of Medical Sciences (Institute of Hematology Chinese Academy of Medical Sciences)

jiangerlie@163.com+86 22 23909018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026